Abstract
The importance of cardiovascular biomarkers in clinical practice increased dramatically in the last years, and the interest extends from the diagnosis purpose to prognostic applications and response to specific treatment. Acute heart failure, ischemic heart failure, and COVID-19 infection represent different clinical settings that are challenging in terms of the proper prognostic establishment. The aim of the present review is to establish the useful role of sST2, the soluble form of the interleukin-1 receptor superfamily (ST2), physiologically involved in the signaling of interleukin-33 (IL-33)-ST2 axis, in the clinical setting of acute heart failure (HF), ischemic heart disease, and SARS-CoV-2 acute infection. Molecular mechanisms associated with the IL33/ST2 signaling pathways are discussed in view of the clinical usefulness of biomarkers to early diagnosis, evaluation therapy to response, and prediction of adverse outcomes in cardiovascular diseases.
Keywords: COVID-19; acute heart failure; biomarkers; risk stratification; sST2.
【저자키워드】 COVID-19, Biomarkers, risk stratification, Acute heart failure, sST2., 【초록키워드】 SARS-CoV-2, therapy, Biomarker, Biomarkers, Diagnosis, risk, cardiovascular diseases, adverse outcomes, adverse outcome, risk stratification, heart failure, early diagnosis, Acute heart failure, interleukin, COVID-19 infection, acute infection, signaling pathway, receptor, prognostic, mechanism, Clinical practice, Signaling, heart disease, ischemic heart disease, molecular mechanisms, clinical setting, specific treatment, IL33, involved, ST2, 【제목키워드】 review, heart, clinical, Prospective, failure, narrative, role,